Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model

Microbial Pathogenesis

Volumn 88, Issue , 2015, Pages 78-86

  Aravind, S ^a   Kamble, Nitin Machindra ^a   Gaikwad, Satish S ^a   Shukla, Sanjeev Kumar ^a   Saravanan, R ^a   Dey, Sohini ^a   Madhan Mohan, C ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Duck enteritis virus; Glycoprotein D; Prime boost; Vaccination

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN D; HERPES VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; RECOMBINANT GLYCOPROTEIN D; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; DNA VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DUCK ENTERITIS VIRUS INFECTION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; VIRAL CLEARANCE; ANIMAL; BLOOD; CELL PROLIFERATION; DISEASE MODEL; DUCK; ENTERITIS; GENETICS; IMMUNIZATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE; MARDIVIRUS; POULTRY DISEASES; SECRETION (PROCESS); VETERINARY;

ANAS; DUCK ENTERITIS VIRUS; MURINAE; MUS; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; DUCKS; ENTERITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTES; MARDIVIRUS; MICE; POULTRY DISEASES; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84940100277     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2015.07.008     Document Type: Article

References (46)

1. Sandhu T.S., Shawky S.A. Duck virus enteritis (duck plague). Diseases of Poultry 2003, 354-363. Iowa State Press, Ames, Iowa. eleventh ed. Y.M. Saif, H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald, D.E. Swayne (Eds.).
2. Wang G., Qu Y., Wang F., Hu D., Liu L., et al. The comprehensive diagnosis and prevention of duck plague in northwest Shandong province of China. Poul. Sci. 2013, 92:2892-2898.
3. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., Ball L.A. Virus Taxonomy: Eighth Report of the International Committee on Taxonomy of Viruses 2005, Elsevier Academic Press, California.
4. Shawky S., Sandhu T., Shivaprasad H.L. Pathogenicity of a low-virulence duck virus enteritis isolate with apparent immunosuppressive ability. Avian Dis. 2000, 44:590-599.
5. Aravind S., Patil B.R., Dey S., Madhan Mohan C. Recombinant UL30 antigen-based single serum dilution ELISA for detection of duck viral enteritis. J. Virol. Methods 2012, 185(2):234-238.
6. Aravind S., Nitin M.K., Satish S.G., Sagar A.K., Dey S., et al. Bioinformatics study involving characterization of synonymous codon usage bias in the duck enteritis virus glycoprotein D (gD) gene. AJAVA 2014, 9(4):229-242.
7. Burgess E.C., Ossa J., Yuill T.M. Duck plague: a carrier state in water fowl. Avian Dis. 1979, 24:940-949.
8. Shawky S., Schat K. Latency sites and reactivation of duck enteritis virus. Avian Dis. 2002, 46:308-313.
9. Kulkarni D.D., James P.C., Sulochana S. Assessment of the immune response to duck plague vaccination. Res. Vet. Sci. 1998, 64:199-204.
10. Shawky S.A., Sandhu T.S. Inactivated vaccine for protection against Duck viral enteritis. Avian Dis. 1997, 41:461-468.
11. Chambal K., Upadhyaya T.N., Goswami S., Dutta B. Studies on the incidence and pathology of naturally occurring duck plague in Assam. Ind. J. Vet. Pathol. 2009, 33:61-69.
12. Akhrameyeva N.V., Zhang P., Sugiyama N., Behar S.M., Yao F. Development of a glycoprotein d-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J. Virol. 2011, 85(10):5036-5047.
13. Zhao Y., Cao Y., Cui L., Ma B., Mu X., et al. Duck enteritis virus glycoprotein D and B DNA vaccines induce immune responses and immunoprotection in Pekin ducks. PLoS One 2014, 9(4):e95093. 15.
14. Dasika G.K., Letchworth G.J. Cellular expression of Bovine Herpesvirus 1 gD inhibits cell-to-cell spread of two closely related viruses without blocking their primary infection. Virol 1999, 245:24-36.
15. Krummenacher C., Carfí A., Eisenberg R.J., Cohen G.H. Entry of herpesviruses into cells: the enigma variations. Adv. Exp. Med. Biol. 2013, 790:178-195.
16. Spear P.G., Longnecker R. Herpesvirus entry: an update. J. Virol. 2003, 77(19):10179-10185.
17. Webre J.M., Hill J.M., Nolan N.M., Clement C., McFerrin H.E., et al. Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases. J. Biomed. Biotechnol. 2012, 612316.
18. Al-Dujaili L.J., Clerkin P.P., Clement C., McFerrin H.E., Bhattacharjee P.S., et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?. Future Microbiol. 2011, 6(8):877-907.
19. Cunningham A.L., Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 2001, 8:6A-10A.
20. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 2008, 59:381-395.
21. Spear P.G. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004, 6(5):401-410.
22. Heldwein E.E., Krummenacher C. Entry of herpes viruses into mammalian cells. Cell. Mol. Life. Sci. 2008, 65:1653-1668.
23. BenMohamed L., Bertrand G., McNamara C.D., Gras-Masse H., Hammer J., et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 2003, 77:9463-9473.
24. Bernstein D.I. Potential for immunotherapy in the treatment of herpes virus infections. Herpes 2001, 8:8-11.
25. Roth K., Ferreira V.H., Kaushic C. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb. Pathog. 2013, 58:45-54.
26. Whitley R.J., Roizman B. Herpes simplex viruses: is a vaccine tenable?. J. Clin. Invest. 2001, 110:145-151.
27. Aravind S., Nitin M.K., Satish S.G., Shukla S., Sagar A.K., et al. Isolation and rapid identification of a Kerala isolate of Duck Enteritis virus using Polymerase chain reaction. J. Pure App. Microbiol. 2014, 8(2):945-949.
28. Gao H., Li K., Gao L., Qi X., Gao Y., et al. DNA prime-protein boost vaccination enhances protective immunity against infectious bursal disease virus in chickens. Vet. Microbiol. 2013, 164:9-17.
29. Guo Z., Wang H., Yang T., Wang X., Lu D., et al. Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus. J. Virol. Met. 2010, 167:84-89.
30. Lowe D.B., Shearer M.H., Jumper C.A., Kennedy R.C. Towards progress on DNA vaccines for cancer. Cell. Mol. Life Sci. 2007, 64:2391-2403.
31. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 2000, 21:163-165.
32. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1992, 1:363-369.
33. Busch D.H., Pamer E.G. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 1999, 189:701-710.
34. Rees W., Bender J., Teague T.K., Kedl R.M., Crawford F., et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4 (+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. 1999, 96:9781-9786.
35. Whalen B.J., Tony H.P., Parker D.C. Characterization of the effector mechanism of help for antigen-presenting and bystander resting B cell growth mediated by Ia-restricted Th2 helper T cell lines. J. Immunol. 1998, 141:2230-2239.
36. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. 1996, 93:2879-2883.
37. Klinman D.M., Yamshchikov G., Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 1997, 158:3635-3639.
38. Koelle D.M., Corey L., Burke R.L., Eisenberg R.J., Cohen G.H., et al. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 1998, 68:2803-2810.
39. Bot A., Antohi S., Bona C. Immune response of neonates elicited by somatic transgene vaccination with naked DNA. Front. Biosci. 1997, 2:173-188.
40. Gonzalez F.A., Milstein C. Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology 1998, 93:149-153.
41. Letellier C., Boxus M., Rosar L., Toussaint J.F., Walravens K., et al. Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology. Vaccine 2008, 26:4840-4848.
42. Tian L., Wang H.N., Lu D., Zhang Y.F., Wang T., et al. The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens. Biochem. Biophys. Res. Commun. 2008, 377:221-225.
43. Liang X., Babiuk L.A., van Drunen Littel-van den Hurk S., Fitzpatrick D.R., Zamb T.J. Bovine herpesvirus 1 attachment to permissive cells is mediated by its major glycoproteins gl, qlll, and glV. J. Virol. 1991, 65:1124-1132.
44. Lan J.M., Gao Z.Y., Xiong H.B., Chuai X., Jin Y.H., et al. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination. Vaccine 2011, 29:6894-6902.
45. Zhang Y., Smith P.M., Bart Tarbet E., Osterrieder N., Jennings R.S., et al. Protective immunity against equine herpesvirus type-1 (ehv-1) infection in mice induced by recombinant ehv-1 gd. Virus Res. 1998, 56:11-24.
46. Law M., Cardoso R.M., Wilson I.A., Burton D.R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 2007, 8:4272-4285.